GSK Coreg Post-MI Survival Backed By Beta Blocker Experience – FDA Cmte.

GlaxoSmithKline's Coreg use in the reduction of post-myocardial infarction mortality is supported by previous experience with other beta blockers in that setting, FDA's cardiovascular advisory committee said